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Plasma  levels  of  mature  BDNF  in  schizophrenia  were  measured  for the  ﬁrst  time.
No  signiﬁcant  difference  was  observed  in  mature  BDNF  levels  in  schizophrenia.
MMP-9  plasma  levels  were  signiﬁcantly  increased  in  patients  with  schizophrenia.
Plasma  mature  BDNF  levels  were  signiﬁcantly  correlated  with  plasma  MMP-9  levels.
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a  b  s  t  r  a  c  t
Brain-derived  neurotrophic  factor (BDNF)  regulates  the  survival  and  growth  of neurons,  and  inﬂuences
synaptic  efﬁciency  and plasticity.  Peripheral  BDNF  levels  in  patients  with  schizophrenia  have  been  widely
reported  in  the literature.  However,  it is  still  controversial  whether  peripheral  levels  of BDNF  are  altered  in
patients  with  schizophrenia.  The  peripheral  BDNF  levels previously  reported  in patients  with schizophre-
nia  were  total  BDNF  (proBDNF  and  mature  BDNF)  as it was  unable  to speciﬁcally  measure  mature
BDNF  due  to  limited  BDNF  antibody  speciﬁcity.  In  this  study,  we examined  whether  peripheral  levels  of
mature  BDNF  were  altered  in  patients  with  treatment-resistant  schizophrenia.  Matrix  metalloproteinase-
9  (MMP-9)  levels  were  also  measured,  as MMP-9  plays  a role  in  the conversion  of proBDNF  to mature
BDNF.  Twenty-two  patients  with  treatment-resistant  schizophrenia  treated  with  clozapine  and  22 age-
and  sex-matched  healthy  controls  were enrolled.  The  plasma  levels  of  mature  BDNF  and  MMP-9  were
measured  using  ELISA  kits. No  signiﬁcant  difference  was  observed  for mature  BDNF  however,  MMP-9  was
signiﬁcantly  increased  in  patients  with schizophrenia.  The  signiﬁcant  correlation  was  observed  between
mature  BDNF  and  MMP-9  plasma  levels.  Neither  mature  BDNF  nor  MMP-9  plasma  levels were  associated
clinical  variables.  Our  results  do not  support  the  view  that  peripheral  BDNF  levels  are  associated  with
schizophrenia.  MMP-9  may  play  a role  in  the pathophysiology  of  schizophrenia  and  serve  as  a  biomarker
for  schizophrenia.Open access under CC BY-NC-ND license.© 2013 The Au
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. Introduction
Schizophrenia is a severe psychiatric disease characterized by
elusions, hallucinations, impairment of cognitive function and
ncoherent behavior. It affects approximately 1% of the general
opulation worldwide. Mounting evidence suggests that a deﬁcit
n neurotrophin supply to cortical neurons may  be an underly-
ng factor in the pathophysiology of schizophrenia as adequate
eurotrophic support is required for normal brain development,
aturation and function [3,4].
Brain-derived neurotrophic factor (BDNF) is a neurotrophin
hat regulates neuronal survival, differentiation and growth dur-
ng brain development, with important effects on neurogenesis
nd neuroplasticity. It is also important for hippocampal-related
earning  and memory [17]. A common single nucleotide polymor-
hism (SNP) of the BDNF gene has impact on episodic memory,
ippocampal morphology and memory-related hippocampal activ-
ty in human [9,16]. Mature BDNF is initially synthesized as a
recursor protein, preproBDNF. Following cleavage of the signal
eptide, proBDNF is converted to mature BDNF by extracellular
roteases, such as matrix metalloproteinase-9 (MMP-9). Mature
DNF and poBDNF each plays important roles in several phys-
ological functions. Recent studies show that mature BDNF and
ro BDNF elicit opposing effects via the TrkB and p75NTR recep-
ors respectively. Mature BDNF preferentially binds to the TrkB
eceptor and plays an important role through BDNF-TrkB signaling
hich fulﬁlls wide variety of functions such as cell survival, migra-
ion, outgrowth of neuritis and synaptic plasticity. In contrast, pro
DNF preferentially binds to the p75NTR receptors and elicit apo-
tosis rather than cell survival [8,11]. Considering the important
oles of mature BDNF, it would be informative to speciﬁcally mea-
ure mature BDNF. Although BDNF levels in human blood can be
easured using commercially available human BDNF ELISA kits,
ue to the limited speciﬁcity of the BDNF antibody, it has not
een possible to distinguish between proBDNF and mature BDNF.
ecently, peripheral levels of mature BDNF have been reported
o be measurable using newly available human BDNF ELISA kits
23].
It is of great interest to assess the potential contribution of BDNF
o the pathophysiology of schizophrenia. Several studies report
ltered BDNF mRNA and protein in prefrontal cortical regions and
ippocampus of post-mortem brain tissues [13,21,22]. Peripheral
DNF levels in patients with schizophrenia have also been widely
eported in the literature. However, there is no widespread agree-
ent on the degree of peripheral BDNF levels in patients with
chizophrenia, as measured in blood serum or plasma. A recent
eta-analysis reported that peripheral BDNF levels were reduced
n schizophrenia. However, there was considerable heterogene-
ty in the results [5]. Considering the important roles of mature
DNF such as cell survival, migration, outgrowth of neuritis and
ynaptic plasticity, it would be informative to speciﬁcally measure
ature BDNF in patients with schizophrenia because dysfunction
able 1
emographic variables for subjects.
Variables Control Patients with schizophrenia
n = 22 n = 22
Age (years) 38.1 ± 12.9 38.1 ± 13.2
Gender (male/female) (12/10) (12/10)
Age at onset – 21.9 ± 8.4
Duration of illness – 17.2 ± 11.1
PANSS positive – 23.0 ± 4.6
PANSS negative – 25.5 ± 5.5
PANSS general – 52.9 ± 9.6
Clozapine dose (mg) – 448.6 ± 130.0
eans ± SD are shown.e Letters 556 (2013) 37– 41
of these mature BDNF roles might be an underlying factor in the
pathophysiology of schizophrenia. The peripheral BDNF levels pre-
viously reported in patients with schizophrenia were total BDNF
(proBDNF and mature BDNF); peripheral levels of mature BDNF
speciﬁcally have not been investigated in patients with schizophre-
nia. This study aimed to determine whether peripheral levels of
mature BDNF were altered in patients with treatment-resistant
schizophrenia.  We  also investigated Matrix metalloproteinase-9
(MMP-9) levels, as MMP-9 plays a role in the conversion of proBDNF
to mature BDNF [8].
2.  Materials and methods
2.1.  Subjects
Twenty-two patients with treatment-resistant schizophrenia
who were treated with clozapine were included in this study.
Twenty-two age- and sex-matched healthy controls also partic-
ipated in this study (Table 1). Cases were recruited at Osaka
University hospitals. Each subject had been diagnosed and assessed
by at least two trained psychiatrists according to the Diagnostic
and Statistical Manual of Mental Disorders, fourth edition (DSM-IV)
criteria based on structured clinical interview. Treatment-resistant
schizophrenia was deﬁned according to the following criteria
mentioned in clozapine drug information in Japan: (1) Non- or
little response to treatment from at least two adequately dosed
antipsychotic trials for at least 4 weeks (including at least one
second-generation antipsychotic, >600 mg/day of chlorpromazine
equivalent) and patients never had the Global Assessment of
Functioning (GAF) scores that were higher than 40. (2) Intoler-
ance to at least two  second-generation antipsychotics because of
uncontrolled extrapyramidal symptoms. All subjects included in
this study met the criteria of non- or little response. Symptoms
of schizophrenia were assessed using the Positive and Negative
Syndrome Scale (PANSS). Cases of schizophrenia with the comor-
bidities of substance-related disorders or mental retardation were
excluded. Controls were recruited through local advertisements.
Psychiatrically, medically and neurologically healthy controls were
evaluated using the DSM-IV structured clinical interview, non-
patient version. Subjects were excluded if they had neurological or
medical conditions that could potentially affect the central nervous
system, such as atypical headache, head trauma with loss of con-
sciousness, chronic lung disease, kidney disease, chronic hepatic
disease, thyroid disease, active stage cancer, cerebrovascular dis-
ease, epilepsy or seizures. Written informed consent was obtained
for all subjects after the procedures had been fully explained.
This study was carried out in accordance with the World Med-
ical Association’s Declaration of Helsinki and approved by the
Research Ethical Committee of Osaka University and Chiba Uni-
versity.
2.2. Measurement of mature BDNF and MMP-9
Plasma levels of mature BDNF and MMP-9 were measured using
the human BDNF ELISA Kit (Adipo Bioscience, Santa Clara, CA, USA),
and the human MMP-9 ELISA Kit (R&D Systems, Minneapolis, MN,
USA), respectively. To minimize assay variance, plasma levels of
mature BDNF and MMP-9 were measured in each subject on the
same day. All experiments were performed in duplicate. Proto-
cols were performed according to the manufacturer’s instructions.
The optical density of each well was measured using an automated
microplate reader (Emax; Molecular Devices, Sunnyvale, CA, USA).
As plasma levels of proBDNF are not measurable by the newly avail-
able proBDNF ELISA kit due to low sensitivity, we measured only
mature BDNF.
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Fig. 1. Plasma levels of mature BDNF and MMP-9 in treatment-resistant schizophrenia tre
and  treatment-resistant patients with schizophrenia who were treated with clozapine (c





















duration of illness were also investigated; no signiﬁcant correla-
T
C
pelation was  observed between plasma levels of mature BDNF and MMP-9 (patients
ith schizophrenia and controls, n = 44, r = 0.333, p = 0.027).
.3. Statistical analysis
Statistical  analyses were performed using SPSS 20.0J software
SPSS Japan Inc., Tokyo, Japan). Differences in clinical characteris-
ics between patients and controls were analyzed using 2 tests
or categorical variables. The groups did not differ with respect
o age or gender (Table 1). Kolmogrov–Smirnov test was used to
est the normality of data distribution. Mature BDNF did not nor-
ally distribute in both patients with schizophrenia and controls
patients with schizophrenia; p = 0.041, controls; p = 0.042). MMP-9
istributed normally in patients with schizophrenia, however did
ot distribute normally in controls (patients with schizophrenia;
 = 0.130, controls; p = 0.012). And differences between patients and
ontrols were analyzed using the Mann–Whitney U-test for contin-
ous variables. Homogeneity of variance was assessed by Levene’s
est. The assumption of homogeneity of group variance was not
iolated in both mature BDNF and MMP-9 levels (mature BDNF; = 0.052, MMP-9; p = 0.112). Test of rejection of Smirnoff–Grubbs
as performed. Spearman rank order correlation test was  per-
ormed to assess the possible correlation between plasma levels
able 2
orrelation analysis.
Clozapine dosage PANSS positive PANSS neg
Mature BDNF 0.901 0.952 0.726 
MMP-9  0.562 0.167 0.574 
 values are shown.ated with clozapine. The plasma levels of mature BDNF and MMP-9 in the controls
ontrol, n = 22, schizophrenia, n = 22).
of  mature BDNF and MMP-9 and clinical characteristics. The signif-
icant level for statistical tests was  set at p < 0.05.
3. Results
The plasma levels of mature BDNF and MMP-9 were compared
between patients with treatment-resistant schizophrenia who
were treated with clozapine and controls, and no signiﬁcant differ-
ence was  observed for mature BDNF (Fig. 1, Mann–Whitney test;
U = 238, p = 0.925). However, MMP-9 was signiﬁcantly increased in
patients with schizophrenia (Fig. 1, Mann–Whitney test; U = 139,
p = 0.016). When we exclude each one sample in both groups
by test of rejection of Smirnoff–Grubbs, MMP-9 was still signiﬁ-
cantly increased in patients with schizophrenia (Mann–Whitney
test; U = 118, p = 0.010). As MMP-9 plays a role in the conversion
of proBDNF to mature BDNF, the correlation between the levels
of mature BDNF and MMP-9 was  examined. There were signiﬁ-
cant correlation between the levels of mature BDNF and MMP-9 in
(Fig. 2, patients with schizophrenia and controls, n = 44, r = 0.333,
p = 0.027). When we investigate this correlation in patients and
controls groups separately, signiﬁcant correlation was observed
in patients with schizophrenia (n = 22, r = 0.585, p = 0.004) but not
in controls (n = 22, r = 0.322, p = 0.143). To determine the effect
of clozapine on mature BDNF and MMP-9 levels, we also exam-
ined the correlation between the plasma levels of mature BDNF
or MMP-9 and clozapine dosage. No signiﬁcant correlation was
observed between the plasma levels of mature BDNF or MMP-
9 and clozapine dosage (Table 2, BDNF and clozapine dosage;
n = 22, r = 0.028, p = 0.901, MMP-9 and clozapine dosage; n = 22,
r = 0.131, p = 0.562). The correlations between the plasma levels
of mature BDNF or MMP-9 and positive and negative symptom
scores on the PANSS were also investigated; no signiﬁcant corre-
lations were observed (Table 2, BDNF and PANSS positive; n = 22,
r = −0.014, p = 0.952, BDNF and PANSS negative; n = 22, r = −0.079,
p = 0.726, MMP-9 and PANSS positive; n = 22, r = 0.306, p = 0.167,
BDNF and PANSS negative; n = 22, r = 0.127, p = 0.574). The corre-
lations between the plasma levels of mature BDNF or MMP-9 andtions were observed (Table 2, BDNF and duration of illness; n = 22,
r = 0.121, p = 0.592, MMP-9 and duration of illness; n = 22, r = 0.087,
p = 0.699).
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. Discussion
In this study, for the ﬁrst time, we measured the plasma lev-
ls of mature BDNF in patients with schizophrenia. The plasma
evels of mature BDNF were decreased in treatment-resistant
chizophrenia,  however the difference did not reach statistical sig-
iﬁcance. Our result was consistent with some previous studies
hat investigated the serum levels of total BDNF in patients with
chizophrenia [10,20]. Treatment-resistant schizophrenia patients
reated with clozapine were enrolled because some studies sug-
est that peripheral BDNF levels increase in association with
ntipsychotics treatment including clozapine which is used for
he treatment of poorly responsive patients with schizophrenia
6,10] and serum BDNF levels were reported to be signiﬁcantly
orrelated with clozapine daily dose but not with typical antipsy-
hotics [15]. However, we found no effect of clozapine treatment
n the plasma levels of mature BDNF. A possible explanation
ould be the difference in race. This is the ﬁrst study inves-
igating the effect of clozapine treatment on the plasma levels
f mature BDNF in Japanese population. Accumulating evidence
uggests that BDNF plays a key role in the pathophysiology of
ajor depressive disorder (MDD). It was reported that BDNF
erum levels in patients with MDD  were signiﬁcantly lower than
hose of healthy controls, and that there was a negative correla-
ion between BDNF serum levels and the severity of depression
n patients [19]. Furthermore, decreased serum levels of BDNF
n antidepressant naive patients with MDD, recovered to lev-
ls associated with amelioration of depressive symptoms, after
ntidepressant treatment. Three meta-analyses and a study using
 large sample size conﬁrmed these ﬁndings [7]. Recently, periph-
ral levels of mature BDNF have been reported to be decreased
n MDD  [23]. Further study using larger samples is needed to
ee whether peripheral levels of mature BNDF are not altered in
chizophrenia and mature BDNF levels are not associated with
lozapine.
We also investigated MMP-9 plasma levels, as MMP-9 plays a
ole in the conversion of proBDNF to mature BDNF [8]. The signif-
cant correlation was observed between mature BDNF and MMP-9
lasma levels, suggesting that MMP-9 plays a role in the conver-
ion of proBDNF to mature BDNF in the samples of this study.
he serum levels of MMP-9 have been reported to be increased
n patients with schizophrenia [2]. A higher frequency of posi-
ive MMP-9 activity in serum from patients with schizophrenia
as also been reported [1]. We  conﬁrmed the presence of ele-
ated plasma MMP-9 levels in patients with treatment-resistant
chizophrenia.  In patients with schizophrenia, MMP9  might be
nduced to recover the decreased mature BDNF. The ﬁnding that
igniﬁcant correlation between mature BDNF and MMP-9 was
bserved only in patients with schizophrenia but not in controls
upports this idea. Plasma levels of MMP-9 have been proposed
o be a useful biomarker for assessing pathological event in
rain. It was reported that levels of MMP-9 in plasma and brain
ere signiﬁcantly correlated after cerebral ischemia in rats [14].
MP-9 is an enzyme implicated in a number of pathological
onditions including neuropsychiatric disorders [18]. A role of
MP-9 in the plasticity of the central nervous system has been
nvestigated in experimental studies and MMP-9 is reported to
e required for hippocampal long-term potentiation and mem-
ry [12]. MMP-9 may  have some roles in pathophysiology of
chizophrenia.
Our study must be interpreted in lights of its limitations.
irstly, the sample size of this study is small. Secondly, only
reatment-resistant schizophrenia patients treated with clozapine
ere included and patients treated with other antipsychotics or
atients without antipsychotics treatment were not included in
his study. Further studies are needed to evaluate the relationship
[
[e Letters 556 (2013) 37– 41
between  plasma levels of mature BDNF and schizophrenia and
clozapine treatment.
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